Zydus Lifesciences will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ingredient in late March, it said on Wednesday.
Indian drugmaker Dr Reddy's Laboratories is likely to launch its generic semaglutide injection in the country in March under the brand name Obeda, according to two people familiar with the matter as ...
The FDA has approved a label expansion for once-weekly tirzepatide for adults with overweight and obesity, allowing the medication to be used with a pen that is equipped with four doses of the drug, ...
Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a ...
The FDA-approved Zepbound KwikPen delivers a full month of treatment in one device and will be available to self-pay patients through LillyDirect starting Feb. 23.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results